Sage Capital Advisors llc purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 17,944 shares of the medical equipment provider’s stock, valued at approximately $2,304,000. Zimmer Biomet Holdings comprises about 1.7% of Sage Capital Advisors llc’s holdings, making the stock its 24th largest position.

A number of other institutional investors also recently added to or reduced their stakes in ZBH. Schulhoff & Co. Inc. boosted its position in Zimmer Biomet Holdings by 6.3% in the second quarter. Schulhoff & Co. Inc. now owns 3,620 shares of the medical equipment provider’s stock valued at $464,000 after buying an additional 215 shares during the period. Neuberger Berman Group LLC boosted its position in Zimmer Biomet Holdings by 16.4% in the second quarter. Neuberger Berman Group LLC now owns 1,480,467 shares of the medical equipment provider’s stock valued at $190,092,000 after buying an additional 208,881 shares during the period. Pacer Advisors Inc. boosted its position in Zimmer Biomet Holdings by 8.3% in the second quarter. Pacer Advisors Inc. now owns 4,598 shares of the medical equipment provider’s stock valued at $590,000 after buying an additional 351 shares during the period. Utah Retirement Systems boosted its position in Zimmer Biomet Holdings by 9.2% in the second quarter. Utah Retirement Systems now owns 36,952 shares of the medical equipment provider’s stock valued at $4,744,000 after buying an additional 3,100 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in Zimmer Biomet Holdings by 16.2% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 47,234 shares of the medical equipment provider’s stock valued at $6,065,000 after buying an additional 6,600 shares during the period. Hedge funds and other institutional investors own 85.47% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 113.19 on Monday. The firm has a market cap of $22.89 billion, a price-to-earnings ratio of 32.24 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a 50-day moving average price of $120.75 and a 200 day moving average price of $120.97.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter last year, the firm posted $2.02 earnings per share. The firm’s revenue was up 1.1% on a year-over-year basis. Analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

ILLEGAL ACTIVITY WARNING: “17,944 Shares in Zimmer Biomet Holdings, Inc. (ZBH) Acquired by Sage Capital Advisors llc” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/28/17944-shares-in-zimmer-biomet-holdings-inc-zbh-acquired-by-sage-capital-advisors-llc.html.

ZBH has been the subject of several research analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $141.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Guggenheim upgraded Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating and set a $157.00 price objective on the stock in a research note on Wednesday, July 12th. BMO Capital Markets restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Jefferies Group LLC restated a “buy” rating and set a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Finally, Bank of America Corporation restated a “buy” rating and set a $158.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $136.75.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.